Gen-Probe's CFO Herm Rosenman says the firm has plenty of catalysts that should drive growth for the next several years.
A large generics business and niche pipeline keep Novartis ahead of the curve.
Day 7: Growth from emerging markets as well as launched and pipeline products bode well for this pick.
Premature disappointment over the prospect of Vanda's sole drug has left investors with a compelling opportunity says Morningstar Opportunistic Investor's Stephen Ellis.
While Warren Buffett may have put the kibosh on a dividend for Berkshire's shareholders, he and the rest of our Ultimate Stock-Pickers continue to hold stocks yielding more than the S&P 500 Index.
©2012 Morningstar Advisor. All right reserved.